Skip to content

Released Aug 8, 2023, before the open

10-Q filed Aug 8, 2023, 39 days after period end · 0001576885-23-000050

Q2 2023 · 10-Q
Revenue—
Net Income-$11.61MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.28N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$13,478,000N/M
Operating Cash Flowderived-$11,670,000N/M
Free Cash Flowderived-$11,670,000N/M

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Net Income-$11.61M-$10.15M-$61.36M-$2.04M
EPS Diluted-$0.28-$0.25-$141.93-$4.86

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR